Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis

BMC Microbiology

Volumn 8, Issue , 2008, Pages

  Hamza, Omar J M ^a   Matee, Mecky I N ^a   Moshi, Mainen J ^a   Simon, Elison N M ^a   Mugusi, Ferdinand ^a   Mikx, Frans H M ^b   Helderman, Wim H Van Palenstein ^b   Rijs, Antonius J M M ^b   Van Der Ven, André J A M ^b   Verweij, Paul E ^b  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; LAMIVUDINE; MICONAZOLE; NEVIRAPINE; NYSTATIN; STAVUDINE; ANTIFUNGAL AGENT;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA TROPICALIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OROPHARYNX CANDIDIASIS; PHENOTYPE; RECURRENT DISEASE; SACCHAROMYCES CEREVISIAE; SPECIES DISTRIBUTION; TANZANIA; YEAST; AIDS RELATED COMPLEX; COMPARATIVE STUDY; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; OROPHARYNX; PATHOLOGY; THRUSH;

CANDIDA ALBICANS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, ORAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OROPHARYNX; RECURRENCE; TANZANIA; YEASTS;

EID: 50049102763     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-8-135     Document Type: Article

References (44)

1. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. DW Feigal MH Katz D Greenspan J Westenhouse W Winkelstein Jr W Lang M Samuel SP Buchbinder NA Hessol AR Lifson GW Rutherford A Moss D Osmond S Shiboski JS Greenspan, AIDS (Acquired Immunodeficiency Syndrome) 1991 5 519 525
2. Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. MI Matee F Scheutz J Moshy, Oral Dis 2000 6 2 106 111 10702788
3. Fungal infections associated with HIV infection. LP Samaranayake PL Fidel JR Naglik SP Sweet R Teanpaisan MM Coogan E Blignaut P Wanzala, Oral Disease 2000 8 151 160 10.1034/j.1601-0825.8.s2.6.x
4. Oral HIV lesions and oral health behaviour of HIV-positive patients attending the Queen Elizabeth II Hospital, Maseru, Lesotho. NH Kamiru S Naidoo, South African Dental Journal 2002 57 479 482 12674869
5. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Campo J Del Romero J Castilla S Garcia C Rodriguez A Bascones, Journal of Oral Pathology and Medicine 2002 31 5 10 10.1034/j.1600-0714.2002.310102.x
6. Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. OJM Hamza MIN Matee ENM Simon E Kikwilu MJ Moshi F Mugusi FHM Mikx PE Verweij AJAM van der Ven, BMC Oral Health 2006 6 12 16916469 10.1186/1472-6831-6-12
7. Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. WG Powderly K Robinson EJ Keath, J Infect Dis 1993 168 2 463 466 8335986
8. Combination of antiretroviral therapy and recent declines in AIDS incidence and mortality. E Vittinghoff S Scheer P O'malley G Colfax SD Holmberg SP Buchbinder, Journal of Infectious Disease 1999 179 717 720 10.1086/314623
9. The changing face of oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment. K Shetty J Leigh, AIDS Patient Care Sexual Transmitted Diseases 2000 14 627 635
10. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. AM Schmidt-Westhausen F Priepke FJ Bergmann PA Reichart, Journal of Oral Pathology and Medicine 2000 31 336 341 10.1034/j.1600-0714.2000.290708.x
11. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients. A UK study. AR Tappuni GJ Fleming, Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 2001 92 623 628 10.1067/moe.2001.118902
12. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. O Nicolatou-Galitis A Velegraki S Paikos P Economopoulou T Stefaniotis IS Papanikolaou T Kordossis, Oral Disease 2004 10 145 150 10.1046/j.1601-0825.2003.00994.x
13. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. FMC Müller M Weig J Peter TJ Walsh, Journal of Antimicrobial Chemotherapy 2000 46 338 341 10.1093/jac/46.2.338 10933673
14. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations. R Pelletier J Peter C Antin C Gonzalez L Wood TJ Walsh, Journal of Clinical Microbiology 2000 38 1563 1568 10747144
15. Fluconazole resistance in Candida glabrata. DW Warnock J Burke NJ Cope EM Johnson NA von Fraunhofer EW Williams, Lancet 1988 1 1310 10.1016/S0140- 6736(88)92919-4
16. Oropharyngeal and esophageal candidiasis in immunocompromised patients: Treatment issues. RO Darouiche, Clinical Infectious Diseases 1998 26 259 274 10.1086/516315 9502438
17. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. P Chavanet J Lopez M Grappin A Bonnin M Duong A Waldner M Buisson P Camerlynck H Portier, AIDS 1994 8 945 950 10.1097/00002030-199407000-00011 7946104
18. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AC Vafray P Drussel F Boerlin J Bohlin-Petzold J Bille MP Glauser JP Chave, AIDS 1994 8 708 709 10.1097/00002030-199405000-00023 8060555
19. Non-albicans oral candidosis in HIV-positive patients. JD Cartledge J Middle BG Gazzard, Journal of Antimicrobial Chemotherapy 1999 43 419 422 10.1093/jac/43.3.419 10223601
20. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. CJ Fichtenbaum S Koletar C Yiannoutsos F Holland J Pottage SE Cohn A Walawander P Frame J Feinberg M Saag C Van der Horst WG Powderly, Clinical Infectious Disease 2000 30 749 756 10.1086/313765
21. In vitro susceptibility of oral Candida to seven antifungal agents. T Kuriyama DW Williams J Bagg WA Coulter D Ready MA Lewis, Oral Microbiology and Immunology 2005 20 349 353 10.1111/j.1399-302X.2005.00236.x
22. Oropharyngeal candidiasis in patients with human immunodeficiency virus: Correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. S Walmsley S King A McGeer Y Ye S Richardson, Clinical Infectious Disease 2001 32 1554 1561 10.1086/320517
23. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. E Blignaut S Messer RJ Hollis MA Pfaller, Diagnostic Microbiology and Infectious Disease 2002 44 169 174 10.1016/S0732-8893(02)00440-6
24. Species distribution and antifungal susceptibility profile of oral Candida isolates from HIV-infected patients in the antiretroviral therapy era. CR Costa JA de Lemos XS Passos CR de Araújo AJ Cohen LK Souza R Silva Mdo, Mycopathologia 2006 162 45 50 10.1007/s11046-006-0032-y 16830191
25. Guide to epidemiology and diagnosis of oral mucosal diseases and conditions. IR Krammer JJ Pindborg V Bezrouukov JS Infirri, Community Dent Oral Epidemiol World Health Organization 1980 8 1 26 10.1111/j.1600-0528.1980. tb01249.x 6929240
26. Application of flow cytometry to the study of HIV infection. A Landay B Ohlsson-Wilhelm JV Giorgi, AIDS 1990 4 479 497 10.1097/00002030-199006000-00001 2201315
27. Laboratory diagnosis of oral candidosis. J Silverman J Migliorati L Epstein LP Samaranayake, Oral Candidosis Butterworth: London, Samaranayake LP, MacFarlane TW, 1990 213 237
28. Oropharyngeal carriage of Candida species in HIV-infected patients in India. HC Gugnani K Becker W Fegeler S Basu D Chattopadhya U Baveja S Satyanarayana T Kalghatgi A Murlidhar, Mycoses 2003 46 299 306 10.1046/j.1439-0507.2003.00896.x 12950898
29. National Committee for Clinical Laboratory Standards, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition M27-A2 National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania, USA 2002
30. Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. DT te Dorsthorst PE Verweij JF Meis JW Mouton, Antimicrob Agents Chemother 2005 49 3341 3346 16048945 10.1128/AAC.49.8.3341-3346.2005
31. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. E Blignaut M Botes H Nieman, SADJ 1999 54 12 605 608 16892568
32. Oral candidiasis and oral yeast carriage among institutionalized South African paediatric HIV/AIDS patients. E Blignaut, Mycopathologia 2007 163 67 73 10.1007/s11046-006-0087-9 17295100
33. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. F Barchiesi D Arzeni MS Del Prete A Sinicco L Falconi Di Francesco MB Pasticci L Lamura MM Nuzzo F Burzacchini S Coppola F Chiodo G Scalise, Journal of Antimicrobial Chemotherapy 1998 41 541 548 10.1093/jac/41.5.541 9630407
34. Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. AA Lattif U Banerjee R Prasad A Biswas N Wig N Sharma A Haque N Gupta NZ Baquer G Mukhopadhyay, Journal of Clinical Microbiology 2004 42 1260 1262 15004088 10.1128/JCM.42.3.1260-1262.2004
35. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. M Martinez JL López-Ribot WR Kirkpatrick BJ Coco SP Bachmann TF Patterson, Journal of Clinical Microbiology 2002 40 3135 3139 12202543 10.1128/JCM.40.9.3135-3139.2002
36. The relevance of Candida species other than Candida albicans as opportunistic pathogens. F Mühlschlegel M Frosch, Mycoses 1999 42 194
37. Detection of Candida dubliniensis in Venezuela. C Hartung de Capriles S Mata-Essayag C Pérez MT Colella A Roselló C Olaizola SM Abate, Mycopathologia 2005 160 227 234 10.1007/s11046-005-6873-y 16205971
38. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. S Redding J Smith G Farinacci M Rinaldi A Fothergill J Rhine-Chalberg M Pfaller, Clin Infect Dis 1994 18 2 240 242 8161633
39. Does long-term itraconazole prophylaxis result in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? M Goldman GA Cloud M Smedema A LeMonte P Connolly DS McKinsey CA Kauffman B Moskovitz LJ Wheat, Antimicrob Agents Chemother 2000 44 1585 1587 10817713 10.1128/AAC.44.6.1585-1587.2000
40. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. EM Johnson DW Warnock J Luker SR Porter C Scully, Journal of Antimicrobial Chemotherapy 1995 35 103 114 10.1093/jac/35.1.103 7768758
41. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. F Barchiesi M Maracci B Radi D Arzeni I Baldassarri A Giacometti G Scalise, Journal of Antimicrobial Chemotherapy 2002 50 999 1002 10.1093/jac/dkf233 12461023
42. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. F Barchiesi AL Colombo DA McGough AW Fothergill MG Rinaldi, Antimicrob Agents Chemother 1994 38 7 1530 1533 7979284
43. Resistance of Candida species to fluconazole. JH Rex MG Rinaldi MA Pfaller, Antimicrob Agents Chemother 1995 39 1 1 8 7695288
44. Management of common symptoms and opportunistic infections in HIV and AIDS. Ministry of Health, The United Republic of Tanzania, National AIDS Control Programme, National Guidelines for the Clinical Management of HIV and AIDS 2005 2 66 75